Date de publication: 27 août 2014
Promoteur – Intermédiaire Financier
UCB SALieu
Description
The project concerns the R&D programme of six highly strategic and amongst the company's most promising drug development projects. The compounds concerned are in different stages of development, and address unmet needs.
Objectifs
The project comprises a number of R&D sub-projects with different durations and objectives. By addressing the unmet medical needs and by offering new treatments with higher efficacy, tolerability and safety, the net economic returns to society should be very high. A project of this type should accelerate research and bring improved quality of life for patients currently suffering from the related illnesses.
Commentaires
Secteur(s)
- Santé - Santé humaine et action sociale
Montant BEI envisagé (montant approximatif)
EUR 148 million
Coût total (montant approximatif)
EUR 440 million
Aspects environnementaux
The R&D is conducted in state of the art buildings and the research and production facilities are subject to regular audits by competent authorities.
Passation des marchés
The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. Procurement procedures followed are in line with industry practice and satisfactory to the Bank.
Statut
Signé - 16/06/2014
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).